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Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, and understanding the molecular changes associated 
with EOC etiology could lead to the identification of novel targets for more effective therapeutic interventions. Glycosylation 
represents a post-translational modification (PTM) of proteins playing a major role in various cellular functions. Moreover, 
glycosylation participates in major pathobiological events during tumor progression, as aberrant expression of glycan structures 
has been shown to contribute in alterations of specific cellular onco-phenotypes, including tumor cell proliferation, migration 
and invasion. This review aims to describe what is currently known about aberrant glycosylation in EOC, and more specifically, 
the contribution of aberrant O-linked glycosylation in EOC progression. We also discuss our findings about the altered GALNT3 
overexpression in EOC and its involvement in disease dissemination through aberrant mucin O-glycosylation, as well as the 
potential to exploit the role of GALNT3 in understanding the general mechanisms of abnormal glycosylation implicated in EOC 
spreading. Further analyses in cancer glycobiology could significantly enhance our understanding of the molecular mechanisms 
of cancer progression, including EOC dissemination, and could lead to the identification of novel biomarkers/therapeutic targets 
for better management of this deadly disease. Biomed Rev 2014; 25: 83-92
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INTRODUCTION
Etiology of epithelial ovarian cancer
Epithelial ovarian cancer (EOC) is a disease that is responsible 
for more cancer deaths among women in the Western world 
than all other gynecologic malignancies (1). EOC lethality 
primarily stems from the inability to detect the disease at 
an early, organ-confined stage, and the lack of effective 
therapies for advanced-stage disease. So there is urgent need 
for new therapeutic targets and a better understanding of the 
mechanisms involved in the spread of ovarian carcinoma. 
EOC is histologically classified into five different carcinoma 
subtypes, including low-grade serous, high-grade serous, 
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endometrioid, mucinous and clear cell (2); among these, serous 
carcinomas represent the most frequent type, comprising 
approximately 80 % of all advanced EOC (2). Recent findings 
indicate that EOC subtypes are different diseases and suggest 
that future biomarker identification and clinical research 
studies should investigate each EOC subtype separately (3). 
 Treatment of EOC includes the combination of surgery 
and platinum based chemotherapy (4). These approaches, in 
addition to hormonal therapy, show up to 80% responsiveness 
in patients, but unfortunately more than 50% of EOC patients 
eventually relapse and will need additional treatments (4). 
Currently, there is no effective adjuvant treatment for EOC 
patients after surgery or chemotherapy.
It is well established that cancer invasion and metastasis 
represent the major cause of treatment failure. Approximately 
70% of women with advanced-stage EOC have widespread 
intraperitoneal metastases, including the formation of 
malignant serous effusions within the peritoneal cavity (1, 2). 
Pleural effusions constitute the most frequent site of distant 
metastasis (FIGO stage IV disease). Unlike the majority of 
solid tumors, particularly at the primary site, cancer cells in 
effusions are not amenable to surgical removal, and failure 
in their eradication is one of the main causes of treatment 
failure. Indeed, despite advances in cytotoxic therapies (5, 
6), only 30% of women with advanced-stage EOC survive 
5 years after initial diagnosis (1). Thus, management of the 
metastatic disease becomes a crucial problem for the treatment 
of EOC. One possible way to resolve this problem is to target 
metastasis-specific pathways with novel therapies. Hence, 
focused identification of novel pro-metastatic mechanisms, 
target pathways and molecules could enhance our chances of 
discovering new and effective therapies.
 Post-translational modifications (PTM) alter the three-
dimensional structures of proteins by covalently binding 
small molecules to them and therefore represent a major 
diversification mechanism for altering protein function. The 
main PTM types include protein covalent modifications such 
as phosphorylation, acetylation, glycosylation, methylation, 
and ubiquitination, and can be classified according to the type 
of the amino acid side chain modified, the category of the 
modifying enzyme, and the extent of reversibility (7). There 
are many documented studies investigating different PTMs 
and their association with cancer progression; among these, 
aberrant glycosylation has displayed rather important role 
in cancer progression (8, 9), including EOC dissemination 
(10). 
PROTEIN GLYCOSYLATION
Glycosylation represents the most complex form of all PTM, 
and is defined by the regulated process of adding lipids 
and carbohydrates to proteins, as this regulation depends 
on various building enzymes and proteases that allow for 
the diversification of protein function. Many studies have 
advanced our understanding of the major roles of glycans, but 
no evidence has yet comprehensively explained their role or 
function under different normal and pathological conditions, 
which is mainly due to their enormous diversity. Glycans have 
been shown to play crucial roles in development, growth and 
the functionality of organisms (11). Cell surface glycans are 
mainly implicated in recognizing molecules that aid in the 
process of communication and adhesion (12). Analysis of the 
SWISS-PROT database showed that the majority of proteins of 
the sequon are glycosylated, as more than 50% of all proteins 
are characterized as glycoproteins (13). Glycosylation of 
proteins is relatively rare in prokaryotes and quite common 
in eukaryotes. Three types of glycosylation of proteins 
are currently known (including C-linked glycosylation, 
N-linked glycosylation, and O-linked glycosylation), but 
C-glycosylation, representing mannosylation of C2 of the 
indole ring of tryptophan residues is quite rare (14), as the 
major glycosylation types represent N-linked and O-linked 
(mucin) glycosylation.
N-linked glycosylation
N-linked-(or asparagine-type) glycosylation represents a 
fundamental and extensive PTM that results in the covalent 
attachment of an oligosaccharide onto asparagine residues of 
the polypeptide chains (15). The N-linked glycosylation of 
glycoproteins takes place in both prokaryotic and eukaryotic 
cells (15). Through the attachment of glycans at asparagine 
residues, N-linked glycosylation promotes protein folding 
by enhancing solubility and mediating interactions between 
nascent proteins and cellular proteins, such as chaperones. 
Three key processes in N-linked glycosylation have been 
identified: (i) the lipid-mediated assembly of monosaccharides 
into glycans, which is performed by various enzymes in 
the endoplasmic reticulum (ER) - Golgi complex; (ii) the 
acceptance of a glycan by the consensus sequence Asn-
X-Ser/Thr (X for any amino acid except proline), and (iii) 
the oligosaccharyltransferase-catalyzed attachment of the 
glycan to the side chain of the asparagine residue (15). The 
initiation step of N-glycan synthesis starts with the transfer of 
GlcNAc-P from UDP-GlcNAc to membrane-bound Dol-P to 
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form GlcNAc-P-P-Dol, and this process is catalyzed by the 
enzyme GlcNAc-1-phosphotransferase (16).  See Figure 1 for 
illustration of the principles of the N-glycosylation. 
O-linked (mucin) glycosylation
O-glycosylation of proteins represents the most diverse PTM 
form. There are several types of O-glycosylation, and they 
have been characterized and differentiated based on their 
biosynthesis and linkage processes. These include: O-GalNAc 
or mucin-type, O-mannose, O-xylose, O-fucose, O-glucose, 
O-galactose and O-GlcNAc (12). The initiation process of 
O-glycosylation, except for O-GalNAc, O-Xyl and O-GlcNAc, 
occurs in the ER. O-GalNAc initiation of proteins takes place 
in the Golgi (12) and the O-GlcNAc glycosylation takes place 
in the cytosol and the nucleus (17).
 O-linked glycosylation mostly happens on serine and 
threonine residues (18), although as recently demonstrated, 
O-glycosylation can also be found on tyrosine residues 
(19). The initiation step of O-glycosylation is more complex 
than N-glycosylation and involves the transfer of different 
monosaccharides to each of the six O-linked glycans. 
O-GalNAc glycosylation is more distinct as it involves two 
Figure 1. Schematic depiction of N-linked glycosylation. N-linked glycosylation is mainly linked to asparagine residues of 
proteins, specifically the Asn-X-Ser/Thr motif. N-linked glycosylation is initiated by en bloc transfer of an assembled complex 
glycan to the Asn residue. N-glycosylation biosynthesis starts with the high-mannose structure, followed by the branching of 
glycans and the addition of a variety of monosaccharides, this process is mainly dependent on the glycosyltransferases present, 
here we show the role of GlcNAc-1-phosphotransferase involved in the initiation process found in the ER-Golgi complex. The 
arrow indicates the transferase involved in the initiation process. The linkage of the first oligosaccharide is depicted with a (-).
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steps including the initiation step which is directed by 20 
GalNAc-transferases, a family of enzymes known as the UDP-
N-acetylgalactosamine: polypeptide N-acetyl galactosaminyl 
transferases (GalNAcTs). Thus, the O-GalNAc initiation step 
involves the transfer of the monosaccharide GalNAc from 
UDP-GalNAc to the hydroxyl group of the serine, threonine 
or tyrosine residues found in the target protein substrate, 
which is followed by a processing step, where 30 or more 
glycosyltransferases create distinct glycan structures (20, 
21). See Fig. 2 for illustration of the principles of GalNAc 
O-glycosylation. 
 As described above, cellular glycosylation mechanisms 
and their biosynthetic pathways are very complex and have 
shown to be fundamental to the changes in glycan processing 
and divergence. Numerous studies have shown that alterations 
in surface glycans are linked to disease progression and most 
importantly in cancer, as these alterations play pivotal roles 
in cancer initiation and progression (22, 23).
ABERRANT GLYCOSYLATION IN CANCER
Cancer cells have been characterized to undergo activation, 
rapid growth, adherence and invasion of neighboring cells/
Figure 2. Schematic depiction of O-linked-(mucin type) glycosylation. O-linked glycosylation is mainly linked to Ser/Thr and 
Tyr residues. O-glycosylation is initiated by transfer of one of six monosaccharides; among these, the GalNAc-type-O-linked 
glycosylation pathway as depicted in the figure. GalNAc-type-O-linked glycosylation is uniquely controlled by the family of 20 
polypeptide GalNAc-transferases located in the Golgi complex. The arrow indicates the genes involved in the initiation process. 
The linkage of the first oligosaccharide is depicted with a (-).
Located in the Golgi  
complex
87
Biomed Rev 25, 2014
Aberrant glycosylation in ovarian cancer
tissues, and these processes are also linked to changes in 
the cell’s glycosylation profiles (24). Studies have provided 
strong evidence for the existence of important link between 
abnormal glycosylation and tumorigenesis. Glycosylation 
changes characterized in cancer cells follow a variety of 
forms, as glycan alterations can be associated with loss 
or gain of expression, depending on the cell type and the 
specific glycan’s structure. Aberrant glycosylation in cancer 
cells could affect certain ligand-receptor interactions and 
more importantly, could favor cancer cell proliferation, 
migration and invasion/metastasis. 
 Altered N-glycosylation of proteins has been reported in 
different cancer types, which has led to the identification of 
biomarkers for cancer prediction and diagnosis (25). Notably, 
the branching of N-glycans is involved in various biological 
functions including signal transduction, cell adhesion, 
proliferation, differentiation, and programmed cell death 
(26). The alteration of the branching alters the activity of 
relevant glycosyltransferases, thus affecting the regulation of 
various malignant processes, including cancer cells invasion 
and metastasis (26). A number of N-glycoproteins has been 
shown to be differentially expressed in different cancer types. 
Notably, differential glycosylation and increased expression 
of some N-linked glycopeptides (including apolipoprotein 
B-100 and alpha-1-antichymotrypsin) has been identified 
in lung cancer serum pools compared to control pools 
(27). Some N-glycans, including ceruloplasmin, alpha-1 
antichymotrypsin, and multimerin-1 were identified as 
biomarkers associated with hepatocellular carcinoma 
(HCC) (28). In addition, a study by Chen et al. (2011) found 
substantial concentration changes in N-linked glycoproteins 
between normal and HCC serum samples, as some of these 
glycoproteins included galectin-3 binding protein, insulin-
like growth factor binding protein 3, and thrombospondin 1, 
previously found to be associated with HCC development 
(28). A strong overexpression of N-glycoproteins, including 
cathepsin L and periostin (proteins, involved in extracellular 
matrix remodeling during metastasis) was shown to be 
associated with aggressive prostate cancer (30). 
 Similarly, O-glycans can play important role in 
cancerogenesis, as they could be in part responsible for the 
attachment, invasion and survival of cancer cells. Studies 
have demonstrated that O-glycan structures are truncated in 
many cancer types (31). Tumors associated with different 
mucin families show complex alterations in glycosylation 
profiles compared to normal cells. Recent studies showed that 
the downregulation of mucins contributes to the alterations 
observed in various cancer cell lines, which is associated with 
disease progression. MUC1 is a glycoprotein integrated in 
the plasma membranes of epithelial cells as MUC1 has been 
repeatedly characterized as a major oncogene in different 
cancer types (32). Indeed, MUC1 is aberrantly glycosylated 
and overexpressed in >90% of breast carcinomas and in 
other cancer types of epithelial origin, including ovarian, 
lung, colon, and pancreatic carcinomas (33, 34). MUC4 has 
also been shown to be responsible for tumor progression 
(35). MUC4 expression has been associated with pancreatic 
cancer, as MUC4 is not expressed in normal pancreatic cells 
or tissue (35). MUC16 (or CA125) is now considered to be 
the most effective marker for early EOC detection and the 
monitoring of EOC reoccurrence after therapy (36).
 The different members of the glycotransferase (GALNAC-
Ts) family were shown to be differentially expressed 
in malignant tumors compared to normal tissue. The 
deregulation in the expression of the different GALNAC-
Ts allows them to play diverse roles in cancerogenesis. 
Thus, GALNT1 is highly expressed in bladder cancer 
tissues, making it a potential prognostic marker in bladder 
cancer (37); GALNT2 is overexpressed in oral squamous 
cell carcinoma (38) and was also found to play a role in 
modifying EGFR glycosylation in HCC, which contributes 
to its malignant phenotype (39). GALNT3 is overexpressed 
in pancreatic cancer, and its suppression significantly 
correlates with pancreatic cancer cell growth inhibition 
(40). We have recently demonstrated that GALNT3 is 
strongly overexpressed in high grade serous EOC tumors, 
as compared to normal ovarian tissue (41). Upregulation of 
GALNT6 stabilizes MUC1 protein by aberrant glycosylation 
in breast cancer cells, which allows the accumulation of the 
MUC1 protein in these cancer cells (42). Further, GALNT6 
is expressed in gastric carcinomas and its expression was 
shown to associate with invasive disease (43). A role of 
GALNT7 in progression of cervical cancer (44) and human 
melanoma (45) has been demonstrated. GALNT9 expression 
was coupled with increased survival of neuroblastoma 
cancer cells making this enzyme a potential prognostic 
marker for this cancer type (46). GALNT10 was found to be 
overexpressed in gastric cancer, as its expression significantly 
correlated with the histological type and degree of this cancer 
type (47). Overexpression of GALNT11 was demonstrated 
in chronic lymphocytic leukemia (48). Mutations in the 
GALNT12 gene were linked to the development of colon 
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cancer (49), and GALNT13 was specifically expressed 
in high-risk neuroblastoma (stage 4) patients, while no 
GALNT13 expression was detected in  healthy individuals 
(50). GALNT14 contributes to the glycosylation of MUC13, 
which was observed to be significantly higher in EOC cells 
compared to their normal counterparts, suggesting a role 
of GALNT14 in EOC carcinogenesis, by directing aberrant 
MUC13 glycosylation (51). Moreover, a positive correlation 
was demonstrated between GALNT14 expression and the 
pro-apoptotic factor TRAIL in pancreatic cancer, indicative 
for a protective role of the GALNT14 enzyme in this cancer 
type (52).
ALTERED GLYCOSYLATION IMPLICATED IN EOC ETIOLOGY
N-linked glycosylation in ovarian cancer
N-glycans play crucial roles that influence some of the 
glycoproteins properties and induce effects on the conformation, 
solubility, and recognition capacity of the proteins by glycan-
binding proteins (16). Deficiencies in N-glycan synthesis 
has lead to a variety of human diseases. Aberrant N-linked 
glycosylation has been also described and investigated in 
ovarian cancer. Several studies have examined this association; 
thus a number of N-glycans displayed aberrant expression 
in different EOC subtypes, as mesothelin was shown to be 
overexpressed in high-grade serous, low-grade serous, and 
transitional-cell carcinomas, while versican and periostin 
were overexpressed in most subtypes of ovarian tumors (29). 
Gubbels et al. (2006) demonstrated that mesothelin-MUC16 
binding is N-glycan dependent, as this interaction was shown 
to facilitate EOC peritoneal dissemination (53). Another study 
by Zhang et al. (2014) investigated the association between 
N-glycosylation alterations in glycoproteins secreted by EOC 
cells and metastasis of the disease. By using metabolic stable 
isotopic labeling, they have revealed a notable decrease in 
bisecting GlcNAc structure, as this decrease was found to 
be associated with a higher EOC metastatic potential (54). 
Interestingly, Anugraham et al have shown an expression 
of bisecting GlcNAc on N-linked glycoproteins, and this 
association was found to highly correlate with MGAT3 gene 
expression, a gene responsible for expressing the enzyme 
implicated in the synthesis of the core of the N-glycans (55). 
Their data demonstrated that definite N-glycan substructures 
and their complexes are associated with specific epigenetic 
programming of synthetic enzymes in EOC (55). These 
studies suggest the involvement of N-glycosylation in EOC 
spreading and metastasis, which further suggests the potential 
use of N-glycans for biomarker development and targeted 
EOC therapy. 
O-linked (mucin-type) glycosylation in ovarian 
cancer
Aberrant mucin-type O-glycosylation is one of the most 
abundant cancer-related PTMs, causing major pathological 
changes that in turn influence growth and survival of cancer 
cells and their ability for invasion and metastasis (31). Changes 
associated with the progression of EOC from primary to 
metastatic disease can affect the expression of certain tumor-
associated antigens (TAA), subject to altered O-glycosylation. 
Thus, MUC1 has been identified as a novel TAA, and several 
studies have demonstrated that MUC1 is overexpressed and 
aberrantly O-glycosylated in most adenocarcinomas (34), in 
addition to being overexpressed on the cell surface of 90% 
of EOC tumors, including metastatic lesions (56). The major 
structural difference observed in tumor-associated MUC1 
compared to a normal MUC1 is that tumor MUC1 contains 
shorter and less dense O-glycan chains, thus exposing more 
regions of the MUC1 protein core (57). This feature of the tumor-
associated MUC1 makes it a possible EOC therapeutic target, 
which could delineate novel approaches for more effective 
EOC therapy. MUC13 represents another mucin associated with 
EOC dissemination. Indeed, MUC13 has been overexpressed in 
EOC compared to normal tissue, and was shown to modulate 
various cellular functions such as cell adhesion and proliferation 
(58). A study by Wang et al. (2013) has provided evidence that 
GALNT14 contributes to the aberrant glycosylation of MUC13 
in ovarian carcinogenesis (51). As mentioned above, MUC16 
(CA125) is strongly associated with EOC pathobiology, as it 
currently represents the only clinically-recognized marker for 
EOC progression (59). A study by Robert et al has characterized 
the expression of several mucin genes in differnet EOC 
histological subtypes (60). They have shown that MUC1, MUC2 
and MUC5AC were overexpressed in EOC, while advanced 
disease was associated with decreased MUC3 and MUC4 levels 
(60). Moreover, other studies have revealed that ovarian cyst 
fluid can be a valuable source of mucins. It has been reported 
that MUC6 is a major component in ovarian cyst mucins (61) 
making it a good candidate to further elucidate the role of cyst 
mucins in tumorigenesis. In addition, MUC9 was also found to 
be highly present in the serum of EOC patients (62). 
 Using an epigenomics approach, we have previously 
shown that DNA hypermethylation occurs in all (including 
less invasive/early) stages of ovarian tumorigenesis, while 
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advanced disease was exclusively associated with DNA 
hypomethylation of a number of oncogenes, implicated in 
EOC progression, including invasion/metastasis (63). These 
experiments identified the GALNT3 gene as hypomethylated 
and overexpressed in high-grade EOC tumors, when 
compared to low-malignant potential EOC tumors and 
normal ovarian tissue (41). Additionally, the GALNT3 
expression significantly correlated with shorter progression-
free survival intervals in women with advanced EOC (41). 
Consecutive short-hairpin (shRNA)-mediated GALNT3 
knockdown experiments were strongly indicative for 
GALNT3 implication in EOC cell proliferation, migration, 
invasion and cell cycle control. Gene expression profiling and 
successive network and pathway analyses confirmed these 
findings, as numerous genes and pathways known previously 
to be implicated in EOC tumor invasion and metastasis were 
found to be downregulated upon GALNT3 suppression, while 
some tumor suppressor genes were induced (41). Moreover, 
GALNT3 knockdown resulted in considerable reduction of 
MUC1 protein in EOC cells, although the transcriptional 
level of MUC1 remained unchanged (41). A significantly 
diminished protein expression of other glycosylated 
proteins in EOC cells upon GALNT3 suppression was also 
observed, suggesting that GALNT3 may influence the post-
translational modification and stabilization of MUC1 and 
other O-glycosylated mucin-like targets in EOC cells (41). 
Also, the GALNT3 knockdown-mediated MUC1 suppression 
promoted the expression of the cell adhesion molecules 
E-cadherin and β-catenin, suggesting that the involvement of 
the GALNT3-MUC1 pathway in EOC invasion could include 
the destabilization of the E-cadherin/ β-catenin complex 
formation (41). Our data specify some of the mechanisms 
of abnormal O-glycosylation in ovarian carcinogenesis and 
the identification of the GALNT3 enzyme as EOC oncogene 
and novel EOC biomarker/possible molecular target for EOC 
therapy. These results warrant further and more profound 
studies of aberrant O-glycosylation in EOC. 
CONCLUSION AND PERSPECTIVES
Glycosylation mediates various events associated with 
important biological expansion of the proteome. Aberrant 
glycosylation of glycan structures is now a new hallmark 
common of neoplastic transformation. Determining glycan 
structures is an essential step towards establishing a more 
comprehensive understanding of their roles in normal and 
pathological conditions, including cancer. In this review we 
focused on discussing the role of aberrant glycosylation in EOC. 
EOC is a highly metastatic disease and the leading cause of 
death from gynecologic malignancy. Hence, understanding the 
molecular changes associated with ovarian cancer metastasis 
could lead to the identification of targets for novel therapeutic 
interventions. Studies of disease-related alterations in glycan 
structures of glycoproteins can also lead to the discovery of 
new biomarkers for early EOC diagnostics and more efficient 
follow-up. Global analysis of proteins and their modifications 
has been majorly dependent on the recent advances in mass 
spectrometry tools for sequencing N- and O- glycans from 
cells and tissues. Progress in the field has developed strategies 
in performing both glycomic and glycoproteomic analysis. 
With these high-throughput technologies the dynamic area 
of N- type and mucin-type O-glycosylation can be further 
explored and their role in tumorigenesis, including that of 
EOC, better understood. Moreover, the discovery of new and 
efficient inhibitors that can target glycosylation biosynthetic 
pathways could play important role in the understanding 
of specific/molecular mechanisms of normal and aberrant 
(disease-related) glycosylation, which undoubtedly will lead 
to the development of new and improved cancer treatment 
strategies, including more efficient EOC therapy.
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